<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35074582</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2653</ISSN><JournalIssue CitedMedium="Internet"><Volume>97</Volume><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia</Title><ISOAbbreviation>J Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Plateaus and reversals evaluated by different methods in patients with limb-onset amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>93</StartPage><EndPage>98</EndPage><MedlinePgn>93-98</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jocn.2022.01.016</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0967-5868(22)00023-6</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the difference in frequency of amyotrophic lateral sclerosis (ALS) reversals and plateaus in limb-onset patients evaluated with different methods.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">One hundred and eighteen patients with limb-onset ALS were prospectively recruited. ALS Functional rating scale-revised (ALSFRS-R) score, total Medical Research Council (MRC) muscle strengthscore and clinical global impression (CGI) score were followed up every three months for at least 1&#xa0;year. The changes between two follow-up points in scores were analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Reversal and plateau in ALSFRS-R score were detected in 26.14% patients between initial and 3-month, 21.19% between 3-month and 6-month, 23.73% between 6-month and 9-month, 19.49% between 9-month and 12-month, respectively. For total MRC muscle score, the percentages were 28.81%, 21.19%, 16.95%, 13.56%, respectively. For CGI score, the percentages were 74.57%, 64.41%, 66.10%, 66.95%, respectively. There was significant difference in the frequency of plateau or reversal between ALSFRS-R scale and total MRC scale over 3-month interval visit (P&#xa0;&lt;&#xa0;0.05), while no significant difference was revealed between CGI scale and ALSFRS-R scale or total MRC scale. The frequency of reversal and plateau were 8.47% at 6-month, 4.24% at 9-month, 3.34% at the last follow-up in both ALSFRS-R score and total MRC score, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Plateaus and reversals in ALSFRS-R score, total MRC score and CGI score are not uncommon in limb-onset patients during follow-up. The combination of ALSFRS-R score and total MRC score could better reflect the relentless progression of ALS. The importance of long-interval follow-up should be stressed in clinical practice.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Nan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking Union Medical College Hospital, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Dongchao</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking Union Medical College Hospital, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xunzhe</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking Union Medical College Hospital, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Liying</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking Union Medical College Hospital, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Mingsheng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Peking Union Medical College Hospital, Beijing 100730, China. Electronic address: liumingsheng_pumch@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>01</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Scotland</Country><MedlineTA>J Clin Neurosci</MedlineTA><NlmUniqueID>9433352</NlmUniqueID><ISSNLinking>0967-5868</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALSFRS-R</Keyword><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Muscle strength</Keyword><Keyword MajorTopicYN="N">Plateaus</Keyword><Keyword MajorTopicYN="N">Reversals</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>25</Day><Hour>5</Hour><Minute>41</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35074582</ArticleId><ArticleId IdType="doi">10.1016/j.jocn.2022.01.016</ArticleId><ArticleId IdType="pii">S0967-5868(22)00023-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>